• Dr Sophia Karagiannis and her team

    Antibody therapy and biomarker discovery team

    Triple negative breast cancer is a sub-type of the disease for which there are currently no targeted treatments. In addition, this form of breast cancer can be more aggressive than others.

  • Breast cancer stem cells Dr Robert Clarke

    Breast cancer stem cells

    There is still so much we need to know about how breast cancer cells escape from the original breast tumour, enter the blood stream and manage to seed new tumours in places such as the bone, lungs and brain.

  • Breast Development team

    Breast Development team

    Although effective treatments for breast cancer exist, there are many patients for whom these treatments don’t work or stop working over time.

  • Cell Death and Inflammation Team

    Cell Death and Inflammation Team

    Cancer cells are extremely resilient and able to survive in harsh conditions, sometimes lingering in the body even after treatment. Finding ways to tackle this resilience will help scientists develop more effective ways to treat breast cancer.

  • Nick Orr

    Complex Trait Genetics Group

    The best way to stop people dying from breast cancer is to stop it occurring in the first place. To do this, we need to be able to identify those most at risk of breast cancer and work out what we can do to prevent them from developing it.

  • Developing a breast cancer vaccine

    Developing a breast cancer vaccine

    Radiotherapy and chemotherapy currently used to treat breast cancer can have harmful side effects. Researchers are developing new therapies that aim to stimulate the body’s immune system to attack and kill breast cancer cells, called ‘immunotherapies’

  • Developing a virus treatment for triple negative breast cancer

    Developing a virus treatment for triple negative breast cancer

    Triple negative breast cancer is a form of the disease which has limited treatment options because it cannot be treated using targeted therapies available for other types of breast cancer.

  • Drug Target Discovery team - Prof Spiros Linardopoulos

    Drug Target Discovery team

    Although effective treatments exist for breast cancer, there are many patients for whom these drugs don’t work or stop working over time. We need to develop the next generation of targeted drugs to ensure that all patients receive the best possible treatment.

  • Endocrinology team

    Endocrinology team

    The Endocrinology team aims to understand how and why some patients’ cancers are resistant and others aren't.

  • Evaluation of Tra2 proteins as potential therapeutic targets in breast cancer

    Evaluation of Tra2 proteins as potential therapeutic targets in breast cancer

    Breast tumours respond to treatments such as chemotherapy and radiotherapy in different ways. Professor David Elliott is studying how two proteins are involved in helping breast cancer cells survive these treatments. His work could lead to new ways to make treatments more effective and ultimately save lives.

Pages